Literature DB >> 7521612

Administration of drugs by infusion pumps in palliative medicine.

A B Thorsen1, N S Yung, A C Leung.   

Abstract

A retrospective study was carried out in 100 adult patients with advanced malignant disease. They were given subcutaneous continuous infusions of medication for symptom relief. The drugs were administered through a butterfly needle inserted subcutaneously in the anterior chest wall using a battery-operated infusion pump. The indications for using this technique were inability to swallow due to deteriorating general condition, oesophageal obstruction, intestinal obstruction, severe nausea and vomiting, terminal dyspnoea and poor pain control with oral opiates. All patients received morphine; other drugs administered through the syringe driver included hyoscine, metoclopramide, cyclizine, dexamethasone and midazolam. Ninety-four patients continued subcutaneous infusion until death. The mean duration of treatment was 9.1 days. The treatment was well tolerated by the patients and controlled their symptoms satisfactorily in the great majority. The use of continuous subcutaneous infusion via a syringe driver gives good symptom control. In the last days of life when the patients have difficulty tolerating oral medication, continuous subcutaneous infusion is a superior alternative to frequent intermittent parenteral injections.

Entities:  

Mesh:

Year:  1994        PMID: 7521612

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.

Authors:  Emilia Barcia; Rodrigo Reyes; Maria Luz Azuara; Yolanda Sánchez; Sofía Negro
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

2.  Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.

Authors:  Emilia Barcia; Alicia Martín; María Luz Azuara; Yolanda Sánchez; Sofia Negro
Journal:  Support Care Cancer       Date:  2006-07-18       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.